SLC5A2 and type 2 diabetes mellitus: Therefore, in this study, we aimed to investigate the effects of adding empagliflozin to the treatment regimen of T2D patients who were not receiving SGLT2 inhibitors or glucagon-like peptide-1 (GLP-1) analogs, focusing on its impact on body composition and muscle strength.